Perrot Serge, Aslangul Elisabeth, Szwebel Tali, Gadhoum Houdha, Romnicianu Sophie, Le Jeunne Claire
Service de Medecine Interne et Consultation de la Douleur, Hôtel Dieu, 1 Place du Parvis Notre Dame, 75004 Paris, France.
Int J Colorectal Dis. 2007 Sep;22(9):1119-21. doi: 10.1007/s00384-007-0310-2. Epub 2007 Apr 18.
Pericarditis is rarely reported in inflammatory bowel disease. Besides its common causes, pericarditis could be related to ulcerative colitis flare or to 5-aminosalicylic acid (5-ASA) treatment.
We report the case of a patient in whom fever, weight loss and pericarditis developed after 16 years of treatment with sulfasalazine for ulcerative colitis, after increasing the daily dosage from 1 to 3 g.
The patient recovered after treatment discontinuation and did not exhibit any recurrence of pericarditis when treatment with mesalazine was introduced.
In conclusion, if pericarditis occurs in ulcerative colitis patients treated with 5-ASA compounds, the treatment should be considered as a possible cause, even after an increase of the dosage. In this case, discontinuation of the treatment and cautious switch to another 5-ASA compound should be tested.
炎症性肠病中很少报告心包炎。除常见病因外，心包炎可能与溃疡性结肠炎发作或5-氨基水杨酸（5-ASA）治疗有关。
我们报告一例患者，在用柳氮磺胺吡啶治疗溃疡性结肠炎16年后，每日剂量从1克增加到3克后，出现发热、体重减轻和心包炎。
停药后患者康复，引入美沙拉嗪治疗时未出现心包炎复发。
总之，如果在用5-ASA化合物治疗的溃疡性结肠炎患者中发生心包炎，即使在剂量增加后，也应考虑该治疗为可能病因。在这种情况下，应尝试停药并谨慎换用另一种5-ASA化合物。
Zotero 插件